Skip to main content

Table 2 Patient-based characteristics

From: [68Ga]Ga-PSMA-11 PET before and after initial long-term androgen deprivation in patients with newly diagnosed prostate cancer: a retrospective single-center study

Pat Age T1 T2 GSC ADT ADT
(days)
CTx Initial PSA
(ng/ml)
PSA after ADT ∑ PSMA-TV at T2 in % of T1 ∑ TL-PSMA at T2 in % of T1
(ng/ml) [% of T1]
1 60 MR CT2 4 + 3 B 219 6 Cycles 80 0.41 0.5 4.50 5.89
2 64 CT1 CT2 5 + 4 L 289 6 Cycles 5.9 0.15 2.5 2.80 4.34
3 59 CT1 CT1 5 + 4 Max 279 6 Cycles 2.49 0.27 10.8 12.62 8.95
4 74 CT1 CT2 4 + 4 Max 149 X 29.14 0.69 2.4 9.65 15.78
5 57 MR CT2 4 + 3 Max 218 X 45.4 0.71 1.6 38.12 94.63
6 74 MR MR 4 + 4 Max 61 X 57.5 1.42 2.5 35.12 28.80
7 73 MR MR 4 + 5 Max 98 X 14.06 0.1 0.7 16.71 11.42
8 74 CT1 MR 4 + 3 Max 115 X 25.8 0.05a 0.2 23.35 2.94
9 79 MR CT1 4 + 5 Max 156 X 42.06 1.9 4.5 44.38 33.59
10 79 MR CT1 4 + 4 B 116 X 17.97 1.52 8.5 53.13 50.02
11 76 CT1 CT1 4 + 3 Max 118 X 100.4 1.93 1.9 39.57 9.29
12 65 MR CT1 4 + 5 Max 155 X 91.5 0.09 0.1 0.00 0.00
13 59 CT1 CT1 4 + 4 Max 81 X 32.9 3.08 9.4 206.69 267.85
14 66 CT1 CT1 4 + 4 Max 168 6 Cycles 107 0.21 0.2 42.53 6.50
15 74 CT1 CT1 4 + 4 Max 174 X 16.17 0.93 5.8 16.96 2.73
16 80 CT1 CT1 4 + 5 Max 253 X 12.07 0.45 3.7 63.50 30.34
17 66 CT1 CT1 3 + 4 Max 205 4 Cycles 31.5 0.05 0.2 0.00 0.00
18 70 CT1 CT1 4 + 4 Max 109 X 21 4.91 23.4 59.97 51.12
19 81 CT2 CT2 4 + 3 Max 102 X 26.13 3.53 13.5 45.78 40.14
20 57 CT2 MR 5 + 4 Max 134 X 36.2 1.34 3.7 52.09 6.18
21 59 CT2 CT2 4 + 3 Max 158 X 23.5 2.26 9.6 93.89 90.35
  1. GSC, Gleason score; ADT, androgen deprivation therapy; CTx, chemotherapy/in all cases Docetaxel; B, bicalutamide 150 mg/d; L, leuprorelin 11.25 mg/3 months; Max, maximal androgen blockade (leuprorelin 11.25 mg/3 months + bicalutamide 50 mg/d)
  2. Changes in PSA and PSMA-derived tumor volumes (primary tumor, lymph node metastases and bone metastases), PSMA-TV and TL-PSMA. Patients with a T2 PSA > 1 ng are in italics
  3. aPatient 8 underwent TUR-P in the meantime